XBP-1 Modulation for Hepatic Lipogenesis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia, hepatic steatosis, and steatohepatitis lack effective targets for modulating de novo hepatic lipogenesis, which is crucial for managing metabolic syndrome and related conditions.
Innovation Solution
Administering nucleic acid molecules that downmodulate or upmodulate the activity of XBP-1 or IRE-1 to regulate de novo hepatic lipogenesis, using methods such as siRNA or antisense molecules to target specific pathways in the liver, thereby treating and preventing dyslipidemia, atherosclerosis, hepatic steatosis, and steatohepatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for dyslipidemia are used, then cardiovascular morbidity and mortality are reduced, but effective modulation of de novo hepatic lipogenesis is not achieved
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism of de novo hepatic lipogenesis by identifying XBP-1 as a key regulatory transcription factor. By focusing on this specific molecular target rather than general lipid metabolism, the invention enables precise modulation of hepatic lipogenesis while maintaining the effectiveness of existing dyslipidemia treatments.
Solution Approach 2:
The patent introduces XBP-1 as an intermediary molecular target that connects existing dyslipidemia treatments with the specific pathway of de novo hepatic lipogenesis. By modulating XBP-1 activity, the invention mediates between current therapeutic approaches and the desired effect on hepatic lipid synthesis, enabling both to work together synergistically.
2Object-affected harmful factors
If de novo hepatic lipogenesis is increased, then hepatic steatosis and dyslipidemia are worsened, but protein secretory function may be compromised
Solution Approach 1:
The patent applies local quality by specifically targeting XBP-1's role in lipogenesis pathways while preserving its function in protein secretion. By using tissue-specific or pathway-specific modulators of XBP-1 activity, the invention selectively affects lipid synthesis without compromising the protein secretory function that also depends on XBP-1.
Solution Approach 2:
The patent employs partial action by modulating XBP-1 activity to a specific degree that is sufficient to control de novo lipogenesis but insufficient to impair protein secretion. This nuanced approach allows selective intervention in lipid metabolism while maintaining normal protein secretory function through precise dosage or conditional activation of XBP-1 modulators.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces or increases de novo hepatic lipogenesis, leading to marked hypocholesterolemia, hypotriglyceridemia, and prevention of liver-related disorders without compromising protein secretory function, providing a novel therapeutic strategy for metabolic syndrome-related conditions.
Implementation Method 1
using methods such as siRNA or antisense molecules to target specific pathways in the liver
Implementation Method 2
using methods such as siRNA or antisense molecules to target specific pathways in the liver
Data Source
AI summary
The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.